• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial.

作者信息

Messas Nathan, Tanguay Jean-François, Lordkipanidzé Marie

机构信息

Department of Medicine, Montreal Heart Institute, Montreal, Québec, Canada.

Faculté de médecine, Université de Montréal, Montréal, Québec, Canada.

出版信息

J Thorac Dis. 2017 May;9(5):E440-E443. doi: 10.21037/jtd.2017.04.46.

DOI:10.21037/jtd.2017.04.46
PMID:28616304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5465104/
Abstract
摘要

相似文献

1
Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial.经皮冠状动脉介入治疗（PCI）支架置入术治疗的高危急性冠状动脉综合征（ACS）患者的个体化抗血小板治疗：来自南极试验的经验教训。
J Thorac Dis. 2017 May;9(5):E440-E443. doi: 10.21037/jtd.2017.04.46.
2
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.一项关于接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者血小板功能引导下抗血小板治疗降阶梯的随机试验。急性冠状动脉综合征慢性抗血小板治疗中血小板抑制反应性测试（TROPICAL-ACS）试验的原理与设计。
Thromb Haemost. 2017 Jan 5;117(1):188-195. doi: 10.1160/TH16-07-0557. Epub 2016 Sep 22.
3
Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.经皮冠状动脉介入治疗术后急性冠状动脉综合征患者个体化抗血小板治疗的疗效和安全性：一项单中心、随机、可行性研究。
J Geriatr Cardiol. 2015 Jan;12(1):23-9. doi: 10.11909/j.issn.1671-5411.2015.01.003.
4
Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.双联抗血小板治疗的持续时间基于冠状动脉支架置入术后的缺血和出血风险。
J Am Coll Cardiol. 2019 Feb 26;73(7):741-754. doi: 10.1016/j.jacc.2018.11.048.
5
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.冠状动脉支架置入术后双联抗血小板治疗延长超过12个月的急性冠状动脉综合征患者的长期预后
Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1176-1184. doi: 10.1002/ccd.26831. Epub 2016 Nov 10.
6
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.氯吡格雷用于冠心病患者的获益与风险：来自随机研究和注册登记研究的证据
Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001.
7
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.非ST段抬高型急性冠脉综合征支架置入术后，高治疗后血小板反应性与心肌坏死的高发生率相关。
Thromb Haemost. 2007 Feb;97(2):282-7.
8
[Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].[急性冠状动脉综合征中的抗血小板治疗：现状与新视角]
G Ital Cardiol (Rome). 2010 Dec;11(12 Suppl 3):27S-33S.
9
[The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].[中国南方经皮冠状动脉介入治疗后接受双联抗血小板治疗患者上消化道出血的发生率、临床特征及危险因素]
Zhonghua Nei Ke Za Zhi. 2016 Jun;55(6):445-50. doi: 10.3760/cma.j.issn.0578-1426.2016.06.009.
10
[Not Available].[无可用内容]
Kardiologiia. 2019 Jan 27;59(1):36-38. doi: 10.18087/cardio.2019.1.10223.

引用本文的文献

1
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome.急性冠状动脉综合征患者的 2 型糖尿病簇的缺血和出血风险。
Intern Emerg Med. 2021 Sep;16(6):1583-1591. doi: 10.1007/s11739-021-02640-z. Epub 2021 Feb 22.
2
Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement.即时血小板功能检测：与动脉血栓形成的相关性及改进机会。
J Thromb Thrombolysis. 2021 Jan;51(1):1-11. doi: 10.1007/s11239-020-02170-z.

本文引用的文献

1
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.一项关于接受经皮冠状动脉介入治疗（PCI）的急性冠状动脉综合征（ACS）患者血小板功能引导下抗血小板治疗降阶梯的随机试验。急性冠状动脉综合征慢性抗血小板治疗中血小板抑制反应性测试（TROPICAL-ACS）试验的原理与设计。
Thromb Haemost. 2017 Jan 5;117(1):188-195. doi: 10.1160/TH16-07-0557. Epub 2016 Sep 22.
2
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial.血小板功能监测以调整急性冠状动脉综合征支架置入老年患者的抗血小板治疗（南极洲研究）：一项开放标签、盲终点、随机对照优势试验
Lancet. 2016 Oct 22;388(10055):2015-2022. doi: 10.1016/S0140-6736(16)31323-X. Epub 2016 Aug 28.
3
Platelet Function Tests.血小板功能测试
Semin Thromb Hemost. 2016 Apr;42(3):258-67. doi: 10.1055/s-0035-1564834. Epub 2016 Feb 29.
4
High on clopidogrel treatment platelet reactivity is frequent in acute and rare in elective stenting and can be functionally overcome by switch of therapy.氯吡格雷治疗时血小板高反应性在急性支架置入术中很常见，而在择期支架置入术中很少见，可以通过治疗转换来功能性克服。
Thromb Res. 2014 Feb;133(2):257-64. doi: 10.1016/j.thromres.2013.11.029. Epub 2013 Dec 6.
5
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding.抗血小板药物治疗后反应性血小板检测用于缺血和出血事件的共识与更新：ADP 相关性。
J Am Coll Cardiol. 2013 Dec 17;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101. Epub 2013 Sep 27.
6
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.普拉格雷 5 毫克在高龄患者中减弱血小板抑制作用，但在非高龄患者中仍保持不劣效于普拉格雷 10 毫克：一项在稳定型冠状动脉疾病患者中的药效学和药代动力学研究——GENERATIONS 试验。
J Am Coll Cardiol. 2013 Aug 13;62(7):577-83. doi: 10.1016/j.jacc.2013.05.023. Epub 2013 Jun 7.
7
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.床边监测调整经皮冠状动脉介入治疗术后抗血小板治疗。
N Engl J Med. 2012 Nov 29;367(22):2100-9. doi: 10.1056/NEJMoa1209979. Epub 2012 Nov 4.
8
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.ACS 患者未血运重建治疗时应用普拉格雷和氯吡格雷延长疗程的血小板功能：TRILOGY ACS 血小板功能亚研究。
JAMA. 2012 Nov 7;308(17):1785-94. doi: 10.1001/jama.2012.17312.
9
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial.在体重较低的患者中，普拉格雷 5 毫克降低血小板反应性不劣于体重较高的患者中普拉格雷 10 毫克：来自 FEATHER 试验的结果。
J Am Coll Cardiol. 2012 Nov 13;60(20):2032-40. doi: 10.1016/j.jacc.2012.08.964. Epub 2012 Oct 17.
10
Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis.基于血小板反应性检测的强化抗血小板治疗对经皮冠状动脉介入治疗后患者的疗效和安全性：系统评价和荟萃分析。
Int J Cardiol. 2013 Sep 1;167(5):2140-8. doi: 10.1016/j.ijcard.2012.05.100. Epub 2012 Jun 15.